BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tagrisso (Osimertinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tagrisso (Osimertinib)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05998993-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tagrisso (Osimertinib): Phase na readout est. (NCT05998993)
DESCRIPTION:Tagrisso (Osimertinib)\, phase na\, Non-Small Cell Lung Cancer.
 \nStudy: Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving O
 simertinib (CULTRO)\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05998993
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256509-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07256509)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Al
 one as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resect
 able Non-squamous Non-small Cell Lung Cancer\nEstimated primary completion
 : 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 simertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07256509
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315113-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT07315113)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Study of NXP900 With Osimertinib in Subjects With Advanced\, EGFR-
 Mutated Non-Small Cell Lung Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073151
 13
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03909334-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03909334)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Osimertinib With and Without Ramucirumab in Locally Advan
 ced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03909334
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04285671-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04285671)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Necitumumab and Trastuzumab in Combination With Osimertinib for 
 the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutate
 d Stage IV Non-small Cell Lung Cancer\nEstimated primary completion: 2 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4285671
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT07376382)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimerti
 nib in Patients With Locally Advanced or Metastatic NSCLC\nEstimated prima
 ry completion: 12 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07376382
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung 
 Cancer With Oncogenic Mutation\nEstimated primary completion: 24 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0432289
 0
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04762199-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT04762199)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant
  Non-small Cell Lung Cancer\nEstimated primary completion: 27 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04762199
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109558-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT06109558)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: The Efficacy and Safety of LMV-12 Combined With Osimertinib in N
 SCLC\nEstimated primary completion: 30 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06109558
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06507306-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT06507306)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1.\nStudy: A Study to Investigat
 e the Safety and Efficacy of KQB198 as Monotherapy and in Combination in P
 articipants With Advanced Solid Malignancies\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 simertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06507306
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04780568-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT04780568)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Tegavivint as First-Line Therapy for the Treatment
  of Metastatic EGFR-Mutant Non-small Cell Lung Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04780568
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322783-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07322783)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Combined With Savolitinib in the Treatment of NSCLC Wi
 th Low Copy Number MET Amplification\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7322783
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413201-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 4 readout est. (NCT04413201)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 4\, Non-Small Cell Lung Cancer.\
 nStudy: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib C
 ompared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negativ
 e Nonsquamous NSCLC\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04413201
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743505-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04743505)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Safety and Efficacy of Combining APL-101 With Frontline Osimerti
 nib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 31 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04743505
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323641-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07323641)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progres
 sive\, Incurable\, Non Small Cell Lung Cancer\nEstimated primary completio
 n: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 simertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07323641
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629234-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05629234)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3.\nStudy: Roll Over StudY for P
 atients Who Have Completed a Previous Oncology Study With Osimertinib (TAG
 RISSO) (ROSY-T)\nEstimated primary completion: 22 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05629234
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02503722-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT02503722)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanc
 ed EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cel
 l Lung Cancer\nEstimated primary completion: 28 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT02503722
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014827-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06014827)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body
  Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive
  Oncogenic Positive Non-Small Cell Lung Carcinoma\nEstimated primary compl
 etion: 9 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06014827
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380348-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06380348)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: JMT101 in Combination With Osimertinib\, Versus Cisplatin-pemetrex
 ed in Participants With Locally Advanced or Metastatic Non-small Cell Lung
  Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) 
 Exon 20ins Mutations\nEstimated primary completion: 26 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03410043-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03410043)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib\, Surgery\, and Radiation Therapy in Treating Patients
  With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations\, NO
 RTHSTAR Study\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03410043
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04410796-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT04410796)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancer
 s\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04410796
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03567642-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT03567642)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1.\nStudy: A Study of the Combin
 ation of Osimertinib\, Platinum and Etoposide for Patients With Metastatic
  EGFR Mutant Lung Cancers\nEstimated primary completion: June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03567642
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485452-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07485452)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Boosting Osimertinib Blood Brain Barrier Penetration\nEstimated pr
 imary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07485452
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498986-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06498986)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Table
 ts in Patients With Locally Advanced or Metastatic Non-small Cell Lung Can
 cer\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06498986
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557096-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT06557096)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therap
 y in EGFR-Mutant Advanced NSCLC\nEstimated primary completion: 1 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06557096
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496663-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT02496663)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant 
 Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a 
 Previous EGFR Tyrosine Kinase Inhibitor\nEstimated primary completion: 30 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 496663
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612137-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2.\nStudy: Study of IBI3005 Co
 mbination Therapy in Participants With Unresectable\, Locally Advanced or 
 Metastatic Solid Tumors\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05642572)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Comparing Combinations of Targeted Drugs for Advanced Non-Small Ce
 ll Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Tr
 ial)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03191149-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03191149)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Testing Osimertinib as a Treatment for Lung Cancers With an EGFR E
 xon 20 Change\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03191149
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03392246-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03392246)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase 2 Study of Osimertinib in Combination With Selumetinib in 
 EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer\nEstimated primary 
 completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03392246
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05880706-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05880706)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib M
 esylate Tablets in Patients With Locally Advanced or Metastatic Non-small 
 Cell Lung Cancer\nEstimated primary completion: July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05880706
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05748093-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Tagrisso (Osimertinib): Phase 4 readout est. (NCT05748093)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 4\, Non-Small Cell Lung Cancer.\
 nStudy: Improving Osimertinib Exposure and Cost-effectiveness Using Pharma
 cokinetic Boosting With Cobicistat\nEstimated primary completion: 1 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05748093
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03040973)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2.\nStudy: Study to Allow Patien
 ts Previously Participating in a Novartis Sponsored Trial to Continue Rece
 iving Capmatinib Treatment as Single Agent or in Combination With Other Tr
 eatments or the Combination Treatment Alone\nEstimated primary completion:
  30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimer
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03040973
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120349-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05120349)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Global Study to Assess the Effects of Osimertinib in Participant
 s With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection\nEsti
 mated primary completion: 2 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05120349
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07669779)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase II Study of AK146D1 in Combination With AK112 in Advanced 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 30 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07329322)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osim
 ertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Gr
 owth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528458-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05528458)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib to Suppress the Progression of Remaining GGN for EGFR 
 Mutation-positive Stage IB-IIIA Lung Adenocarcinoma\nEstimated primary com
 pletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05528458
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04591002-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT04591002)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2.\nStudy: Osimertinib to Suppre
 ss the Progression of GGN(EGFR Mutation-positive)\nEstimated primary compl
 etion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04591002
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03667820-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03667820)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in
  EGFR Mutant NSCLC\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03667820
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05801029)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate Safety and Efficacy of Osimertinib and Amiv
 antamab in Participants With Non-small Cell Lung Cancer With Common Epider
 mal Growth Factor Receptor Mutations\nEstimated primary completion: 1 Octo
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 01029
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05166616-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT05166616)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutat
 ed Non-Small Cell Lung Cancer\nEstimated primary completion: 28 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05166616
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06142617)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Prospective Study of Pembrolizumab Combining Chemotherapy in Adv
 anced NSCLC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06142617
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07038460)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Multicenter Phase II Randomized Trial of Limertinib Followed by 
 Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chem
 otherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NS
 CLC\nEstimated primary completion: December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785741-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT05785741)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2.\nStudy: A Study of DB-1310 
 in Advanced/Metastatic Solid Tumors\nEstimated primary completion: 30 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 785741
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07603791)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Phase II Clinical Study to Evaluate the Safety\, Tolerability\, Ph
 armacokinetics and Antitumor Activity of ALK202 for Injection in Combinati
 on With Drugs in NSCLC Participants.\nEstimated primary completion: 30 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7603791
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06692491)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2.\nStudy: Study of Precision Tr
 eatment for Rare Tumours in China Guided by PDO and NGS\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06692491
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918782-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06918782)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Real-world Experience With Combination Chemotherapy and Osimertini
 b in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06918782
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT02465060)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2.\nStudy: Targeted Therapy Dire
 cted by Genetic Testing in Treating Patients With Advanced Refractory Soli
 d Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401110-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT05401110)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Osimertinib With Carotuximab in Advanced\, EGFR-mutated N
 on-Small Cell Lung Cancer\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05401110
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505173-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07505173)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Hippocampus-Protective Radiotherapy Combined With Osimertinib for 
 Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer\nEstimated primar
 y completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07505173
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06829459)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Glumetinib Combined
  With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N
 on-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimate
 d primary completion: 15 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06829459
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586453-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03586453)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib In EGFR Mutant Lung Cancer\nEstimated primary completi
 on: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03586453
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824792-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tagrisso (Osimertinib): Phase 4 readout est. (NCT06824792)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 4.\nStudy: Optimal Standard Trea
 tment Selection for Solid Tumor Patients by Biologically-informed Multi-ag
 ent System\nEstimated primary completion: 29 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06824792
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486833-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04486833)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients W
 ith Advanced Lung Cancer Who Progressed on Osimertinib\nEstimated primary 
 completion: March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04486833
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Ivonescimab in Combination With Dato-DXd or Osimertin
 ib in People With Non-Small Cell Lung Cancer\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07535437
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712680-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT06712680)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced 
 Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treatin
 g Patients With Advanced NSCLC Positive for Driver Genes\nEstimated primar
 y completion: 10 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06712680
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361705-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT07361705)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
 \nEstimated primary completion: 23 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07361705
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375316-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07375316)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A ctDNA-guided Phase II Trial of Osimertinib in Combination With S
 acituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positi
 ve ctDNA After lead-in Osimertinib Monotherapy\nEstimated primary completi
 on: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osi
 mertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07375316
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06486142)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Stud
 y\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206498-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281014
DTEND;VALUE=DATE:20281015
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07206498)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With
  Osimertinib for NSCLC\nEstimated primary completion: 14 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07206498
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911449-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07911449)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-M
 utant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases\nEstima
 ted primary completion: 30 October 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07911449
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833154-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT03833154)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Plac
 ebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC)
  Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresec
 ted NSCLC Harboring an EGFR Mutation\nEstimated primary completion: 31 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 833154
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895928-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06895928)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2.\nStudy: A Trial of SHR-A2102 
 With Other Antitumor Therapies in Advanced Solid Tumors\nEstimated primary
  completion: December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06895928
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07622186)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of SKB571 Combination Therapy in Participants With Non-Sma
 ll Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908772-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT06908772)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: Glumetinib Combined With Osimertinib Treatment for Non-Small Cel
 l Lung Cancer Patients\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06908772
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06206850-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06206850)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resista
 nce to Neoadjuvant Osimertinib\nEstimated primary completion: January 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06206850
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709274-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tagrisso (Osimertinib): Phase na readout est. (NCT06709274)
DESCRIPTION:Tagrisso (Osimertinib)\, phase na\, Non-Small Cell Lung Cancer.
 \nStudy: Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCL
 C\nEstimated primary completion: January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06709274
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058519-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290124
DTEND;VALUE=DATE:20290125
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07058519)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EG
 FRm+ Monitoring in NSCLC\nEstimated primary completion: 24 January 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07058519
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153055-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07153055)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2.\nStudy: Lurbinectedin With 
 Osimertinib in Transformed Small Cell Lung Cancer\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/os
 imertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07153055
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486648-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07486648)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alt
 erations Following Prior 1L Osimertinib\nEstimated primary completion: 15 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 86648
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295821-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07295821)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Induction and Maintenance for Chemo-ineligible Stage I
 II Unresectable EGFR+ NSCLC: Single-arm Study\nEstimated primary completio
 n: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osime
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07295821
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06436144-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06436144)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Etoposide as First-Line Treatment in Osimertinib-R
 esistant Advanced EGFR-Mutant NSCLC\nEstimated primary completion: June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06436144
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546866-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05546866)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in
  NSCLC With Uncommon EGFRm\nEstimated primary completion: 30 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05546866
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumor
 s\nEstimated primary completion: 2 November 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05526755-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20291122
DTEND;VALUE=DATE:20291123
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05526755)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected 
 Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carc
 inoma (NSCLC)\nEstimated primary completion: 22 November 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05526755
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710612-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07710612)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase 2 Study of ABSK043 Combined With Osimertinib\nEstimated pr
 imary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07710612
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142189-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Tagrisso (Osimertinib): Phase 1 readout est. (NCT05142189)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Trial Evaluating the Safety\, Tolerability and Preliminar
 y Efficacy of BNT116 Alone and in Combinations in Patients With Advanced N
 on-small Cell Lung Cancer\nEstimated primary completion: February 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05142189
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279935-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Tagrisso (Osimertinib): Phase 4 readout est. (NCT07279935)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 4\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Combined With Chemotherapy in Patients Who Had Distant
  Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC
 .\nEstimated primary completion: 18 May 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07279935
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073365-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07073365)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Bolstering Outcomes After Induction With Osimertinib Plus Chemothe
 rapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)\n
 Estimated primary completion: 30 June 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07073365
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155187-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT07155187)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Adverse Events and Change in Disease Activity 
 of Intravenous (IV) Telisotuzumab Adizutecan\, Monotherapy or in Combinati
 on With Osimertinib\, Compared to Standard of Care in Adult Participants W
 ith Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cel
 l Lung Cancer\nEstimated primary completion: September 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07155187
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874490-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07874490)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NS
 CLC\nEstimated primary completion: December 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07874490
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2.\nStudy: A Study to Evaluate
  the Safety\, Tolerability\, Drug Levels\, and Preliminary Efficacy of BMS
 -986507 Combinations in Adult Participants With Advanced Solid Tumors\nEst
 imated primary completion: 26 February 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06053099-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Tagrisso (Osimertinib): Phase na readout est. (NCT06053099)
DESCRIPTION:Tagrisso (Osimertinib)\, phase na\, Non-Small Cell Lung Cancer.
 \nStudy: A Prospective Cohort Study to Evaluate Molecular pRognostic Facto
 rs and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Compl
 etely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mut
 ations (L858R and Del19)\nEstimated primary completion: October 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06053099
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680790-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT07680790)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Izalontamab Brengitecan (BMS-986507) in Combination With 
 Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination W
 ith Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZA
 BRIGHT-Lung02)\nEstimated primary completion: 30 December 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07680790
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-1958@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity of
  Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as F
 irst-Line Treatment in Adult Participants With Locally Advanced Unresectab
 le or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: November 2036. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
